Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05857371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy

Study acronym: SURF
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2023 to Mar 13, 2024 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date changed from estimate of Nov 2023 to Mar 13, 2024
    • Study sites: 0 to 1
  3. Start date: Sep 2023 to Nov 2023 Primary completion date: Sep 2027 to Nov 2027v2 Show 1 more changeShow less
    • Primary completion date: Sep 2027 to Nov 2027
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SURF is a randomised controlled, parallel group, single blind phase II study designed to assess the safety and potential efficacy of an innovative therapeutic strategy for urethral stenosis based on adjuvant injection of autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF) during endoscopic urethrotomy (standard care).
Trial Details
NCT Number NCT05857371
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Urethral Stenosis
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov